Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)
Of Interest
Breakthrough provides potential for precise melanoma treatment
A major step forward has been made in predicting how well melanoma patients would respond to treatment, thanks to world-leading University of Otago—?t?kou Whakaihu Waka research.
Assay Shows Promise for Early-Stage Melanoma Risk Assessment Beyond SLNB
A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not undergo sentinel lymph node biopsy (SLNB).
Blocking an enzyme may improve melanoma immunotherapy outcomes
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in a specific subset of macrophages), plays a key role in immunotherapy resistance. Blocking HPGDS may be a new way to overcome immunotherapy resistance in melanoma patients and potentially in other tumors facing similar challenges. The results of this study were published in Cancer Discovery.